鉴于苯溴马隆和苯碘达隆的肝毒性,西班牙药物安全委员会建议采取下列措施:1、苯碘达隆(benziodarone,Dilafurane)及苯溴马隆-别嘌醇复合制剂从市场撤出;2、苯溴马隆(benzbromarone,Urinorm)将严格限制使用,即必须经医学专家(风湿病学家或肾病学家)处方,用于对别嘌醇耐药的患者( In view of the hepatotoxicity of benzbromarone and benzodine, the Spanish Medicines Safety Commission recommends the following measures: 1. withdrawal of benziodarone (Dilafurane) and benzbromarone-allopurinol complex from the market; 2, benzbromarone (benzbromarone, Urinorm) will be strictly limited use, that must be medical experts (rheumatologists or nephrologists) prescription, for allopurinol resistant patients (